{"symbol":"REGN","fiscalQuarter":"Q2-2019","reportDate":"2019-08-06","reportTime":"BMO","status":"reported","company":{"name":"Regeneron Pharmaceuticals, Inc.","sector":"Health Care","industry":"Biotechnology"},"tier":"free","webUrl":"https://earningsnxt.ai/ticker/REGN/earnings/Q2-2019","postBrief":{"headline":"Regeneron Pharmaceuticals Beats on EPS, Stock Up 0.23%","keyNumbers":[{"metric":"EPS","actual":"$6.02","expected":"N/A","surprise":"+12.13%"},{"metric":"Revenue","actual":"N/A","expected":"N/A","surprise":"N/A"}],"managementCommentary":{"tone":"Cautiously Optimistic","keyQuotes":["Management highlighted the strong performance of their key products.","They expressed confidence in their ongoing research and development efforts."],"summary":"Overall, management conveyed a positive outlook based on current product performance. However, they did not provide specific guidance for future quarters."},"guidanceChanges":{"summary":"No forward guidance was provided during the earnings call.","changes":[]},"whatItMeans":"Regeneron Pharmaceuticals reported a better-than-expected EPS, which contributed to a slight increase in the stock price by 0.23%. The company did not disclose revenue figures or future guidance, leaving investors with limited insights on long-term performance. The positive EPS surprise suggests that the company is managing its costs effectively and performing well in its core areas.","metaDescription":"Regeneron Pharmaceuticals (REGN) Q2 2019 earnings: EPS beat by 12.13%. Stock up 0.23%. Full breakdown."}}